Stockreport

Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF Vincent Angotti, CEO, highlighted the completion of a $17 million two-tranche financing, including a $5 million strategic minority investment from CorMedix, which grant [Read more]